2nd Swiss Russian Health Forum
Basel September 10 and 11, 2012
Welcome in Basel!

The Swiss Russian Forum Foundation (SRF), created in 2006 as a non-profit organisation under Swiss Law, runs four platforms: Law, Finance, Science and Technology and, last but not least, Health.

In October 2011, the Swiss Russian Health Forum was launched in Moscow. This Conference on Healthcare was very successful as an initial event, but the really good news is, in fact, that several ideas of cross-country cooperation in various fields became concrete projects which in the meantime have been realised.

And now we are looking forward to the second edition of the Swiss Russian Health Forum in Basel, a truly ideal venue for an international gathering on healthcare: doctors, scientists, students, as well as representatives of the pharmaceutical and the medtech industries and politicians will get together at the University of Basel for two days of professional discussions and interdisciplinary networking...

Welcome!

Béatrice G. Lombard-Martin
Executive President, Founder, Swiss Russian Forum

Dear Participants of the Swiss-Russian Health Forum

This is already the second time when you gather to discuss the most burning issues of the public health in Switzerland and in Russia, new approaches and the best practices in treatment of various diseases that pose a threat to our nations.

I am glad that today my country, Switzerland, is hosting this event. Moreover, it is a real pleasure to realise that the idea of the Swiss Russian Health Forum once introduced in Moscow back in 2010 by the Swiss Embassy and the Swiss Russian Forum Foundation lives and is supported by the Swiss and Russian medical communities and business.

It is also very important that our political leaders who set up priorities for further development of our countries strongly back this event and cooperative endeavors between our countries in this field, as improving life quality of people is the top priority both in Switzerland and in Russia.

Our countries are well-known world-wide for their scientific achievements. And rallying our intellectual forces to combat diseases will definitely result in a better life quality of our peoples.

Therefore, I strongly encourage you to meet your colleagues, to share your experiences, to form partnerships, to expand your horizons – for we should not rest on our past and present accomplishments – on the contrary, they should serve as an incentive for our further development.

And I am sure that the Swiss Russian Health Forum that is taking place in Basel, the Swiss and World Life Sciences Hub, will be instrumental in this respect. Our countries can offer a lot to each other and we should use this opportunity. I wish you all the best in your work!

Pierre Helg
Ambassador of Switzerland to the Russian Federation
2nd Swiss Russian Health Forum

Topic in Focus:
Haematology/Oncology

Date:
September 10/11, 2012

Venue:
University of Basel,
Petersplatz 1
Basel, Switzerland

Welcome:
September 09, 2012, University Hospital Basel,
7.30 p.m. by the Canton and the City of Basel

Special:
September 10, 2012 at 12.00 „SENSELESS – A Forum with a difference“, cultural welcome

Organisation

Contacts:
Béatrice G. Lombard-Martin, Executive President:
info@swissrussianforum.org
Dasha Dashina, Project Manager:
dashina@swissrussianforum.org

Andrey Melnikov, Science Officer at Swiss Embassy Moscow:
andrey.melnikov@eda.admin.ch
Dmitri Kuznetsov, (MD), Professor, N.I. Pirogov Russian National Research Medical University:
kuznano@mail.ru (abstracts/publications)

Medtech Switzerland serves the Swiss medtech industry by facilitating export activities to key world markets. This non-profit association was initiated by the Swiss Government and incorporated by Osec and the Medical Cluster.

Gazprombank (Open Joint-Stock Company) is one of the top three banks in the Russian Federation and is rated as the third largest in the Central and Eastern Europe. Gazprombank has investment grade rating from Moody’s Investor’s Service with long-term local and foreign currency debt and deposit ratings at Baa3 with stable outlook. Long-term credit rating from Standard & Poor’s stands at BBB- with stable outlook.

www.gazprombank.ru

General License of the Bank of Russia № 354
Gazprombank (Open Joint-Stock Company)
Introduction

The interdisciplinary aspect of the inaugural SRHF in Moscow last October turned out to be of central importance for its success: the Second Edition of the Health Forum in Basel will therefore again bring together doctors, scientists and representatives of the Pharmaceutical and Med-tech industries, as well as key political figures: innovative cooperation models are to be discovered, new target groups will be approached and different political requirements will be discussed.

The Three Major Issues of the 2nd Swiss Russian Health Forum

Following the advice of our Swiss and Russian partners and based on the experience of last year we will highlight only a limited number of medical disciplines at each SRHF:

• Regulatory Conditions
• Medicine and research
• New Technologies

The opening part of this year’s SRHF will be devoted to Regulatory and Legal Requirements in Healthcare. Topics which are of paramount importance to cross-national cooperation shall be looked into in detail, such as authorization, registration and licencing of pharmaceutical products, medical devices and generic drugs. The protection of intellectual property, standards, and specifications for production, trade, import and export round up this part.

Then on the second day the emphasis is put on innovative treatments in medical disciplines. This year Haematology/Oncology will be the topic in focus and New Technologies will concentrate on Advanced Laboratory Techniques in Blood Studies, Trends in Nanotechnology, Personalised Medicine as well as ICT in Healthcare.

Postgraduates

Particular emphasis will be put on furthering and supporting young doctors and scientists: Postgraduates are invited to contribute to the SRHF’s first poster exhibition and discuss their research with leading experts and professors in the field.

Scientific Publications

An important new feature of the 2nd SRHF will be the scientific publications, extending the information to an additional public: Speakers at scientific sessions can have their abstracts published in the scientific magazine “British Journal of Medicine and Medical Research”, edited by ScienceDomain International (Delhi – London – Boston). The journal’s Editor-in-Chief is Professor Vladimir Kuznetsov.

Organiser

Swiss Russian Forum Foundation – a non-profit organisation according to Swiss law, domiciled in Zurich

Co-organiser

• Association of organizations and institutions of support and development of public health and medical industry, domiciled in Moscow
• IBS Expo Advertising Agency, domiciled in Moscow

Cooperation

• Canton of Basel
• Russian Association of Organisations & Institutions of Support and Development of Public Health and Medical Industry (AZMP)
• N.I. Pirogov National Research Medical University, Moscow
• Almazov, Federal Heart, Blood and Endocrinology Centre, St. Petersburg
• Blokhin Centre, Moscow
• University Hospital Basel
• Swiss Biotech Association
• Universities of Basel, Berne, Zurich, Lausanne, Geneva
• Ministries of Health of Switzerland and the Russian Federation

Advisory Inputs

• Swiss Academy of Medical Sciences
• Russian Academy of Medical Sciences

Changing the practice of medicine

At Novartis, we want to discover, develop and provide high-quality healthcare solutions to address the evolving needs of patients and societies worldwide. We believe that our diverse healthcare portfolio, our dedication to innovation, and our responsible approach will enable us to fulfill our mission to care and to cure.
Merck Serono is the biopharmaceutical division of Merck, a global pharmaceutical and chemical company with total revenues of €10.3 billion in 2011. As the group’s largest division, Merck Serono’s total revenues for 2011 were €5.9 billion.

With headquarters in Darmstadt, Germany, Merck Serono is a global biopharmaceutical business. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono offers leading brands in 150 countries to help patients with cancer (Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride), (Egrifta®, tesamorelin) as well as cardiometabolic diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products are available in all markets.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurodegenerative diseases, oncology and rheumatology.

Merck Serono was established on January 5, 2007, following the acquisition of Serono by Merck and the integration of its business with the former Merck Ethicals division.

With a history that began in 1668 and a future shaped by more than 40,000 employees in 68 countries, Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For further information, please visit www.merckserono.com or www.merckgroup.com

Ferring Pharmaceuticals

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology.

Ferring has its own operating subsidiaries in 50 countries and markets its products in more than 70 countries. To learn more about Ferring or its products please visit www.ferring.com
## 2nd Swiss Russian Health Forum

### Programme

#### Day 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00</td>
<td>Opening Plenary</td>
<td>033 (Aula)</td>
</tr>
<tr>
<td>13.00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14.30</td>
<td>Regulations and Legal Environment</td>
<td>033 (Aula)</td>
</tr>
<tr>
<td>15.00</td>
<td>Intellectual Property and Market Entry</td>
<td>033 (Aula)</td>
</tr>
<tr>
<td>15.30</td>
<td>Personalised Medicine</td>
<td>033 (Aula)</td>
</tr>
<tr>
<td>18.30</td>
<td>Departure to Novartis Campus</td>
<td></td>
</tr>
</tbody>
</table>

#### Day 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Reproductive Endocrinology</td>
<td>117</td>
</tr>
<tr>
<td>10.30</td>
<td>Coffee</td>
<td>118</td>
</tr>
<tr>
<td>10.45</td>
<td>Haematology/Oncology</td>
<td></td>
</tr>
<tr>
<td>12.45</td>
<td>Lunch</td>
<td>033 (Aula)</td>
</tr>
<tr>
<td>13.45</td>
<td>Haematology/Oncology</td>
<td>118</td>
</tr>
<tr>
<td>15.45</td>
<td>Coffee</td>
<td>118</td>
</tr>
<tr>
<td>16.00</td>
<td>Laboratory Techniques in Blood Studies/Nanotechnology</td>
<td>118</td>
</tr>
<tr>
<td>17.30–18.00</td>
<td>Technical Advances over the next decade (Round Table)</td>
<td>033 (Aula)</td>
</tr>
</tbody>
</table>
Welcome of Russian Guests in Basel

19.30 University Hospital Basel

DAY 1

Cultural Welcome

Monday, September 10

12.00 SENSELESS – A Forum with a difference
Helping to reduce the SENSELESS number of lives lost through lack of diseases awareness.

Closing by
• Igor V. Reshetov (MD), Professor, Corresponding Member of Russian Academy of Medical Sciences, Head of Microsurgery department of Moscow Scientific Research Institute of Oncology, P.A. Herzen, Moscow

Welcome Addresses and Keynote Speeches

Monday, September 10

13.00 Welcome by
• Pierre Helg, Ambassador, Embassy of Switzerland to the Russian Federation in Moscow
• Béatrice Lombard-Martin, Executive President of the SRHF
• Carlo Conti, Minister of Health of the Canton Basel, Deputy Head of the Government of the Canton Basel, Chairman of the Conference of Cantonal Health Ministers, President of the Board of Swissmedic

Keynote speeches by
Healthcare System – Challenges in the Socio-Economic Environment in Switzerland
• Alain Berset, Swiss Federal Councillor, Head of the Federal Department of Home Affairs FDHA, Berne

Healthcare System - Challenges in the Socio-Economic Environment in the Russian Federation
• Igor Kagramanyan, Deputy Minister of Health and Social Affairs, Moscow
• Sergey Muraviev, Head Department of International Cooperation and Public Affairs Ministry of Health, Moscow
• Valeriy Chereshnev, Chairman of the Science Committee of the State Duma, Moscow

Regulations and Legal Environment

Monday, September 10

Registration and Harmonisation of Medical Products in Switzerland
• Petra Doerr (MD), Board Member of Swissmedic, Berne

New opportunities and challenges of the Russian Pharma 2020 program: overview of clinical trial and pharmaceutical development environments
• Vladimir Bogin, (MD), ABIM, CEO Cromos Pharma, LLC, Chairman of the Board Medistem Inc. and Tross Laboratories, LLC, Moscow

Opportunity of Russian Health Technology Assessment System Development
• Ramil Khabriev (MD), Professor, Member of Russian Academy of Medical Sciences, a.i. Vice-Principal of the Russian State Medical University after N.I. Pirogov, Moscow

Clinical Research and Clinical Trials in Switzerland
• Jürg Lustenberger (PhD), Dipl. Pharm. Med. SwAPP, Clinical Trials Centre, University of Zurich, Zurich

Practical Experience of Pharmacoeconomics Models for Russian HTA Systems
• Roza Yagudina (MD), Professor, Head Department of Organisation of Medical Supply, First Moscow Medical State University I.M. Sechenov, Moscow

Off label use in Switzerland
• Jürg Nadig (MD), MAE, President Swiss Society of Medical Oncology, Bülach

Intellectual Property and Market Entry

Monday, September 10

Environment for Drug Development in Switzerland and the Russian Federation – Distinctions and Synergies
• Stefan Kohler (PhD), Attorney-at-law, Head of Life Sciences Group, Vischer Ltd, Basel/Zurich

How to Protect, Develop and Bring onto the Market your Drug Innovation in the Russian Federation?
• Vladimir G. Shipkov, Association of International Pharmaceutical Manufacturers (AIPM), Moscow (tbd)

How to Protect, Develop and Bring onto the Market your Drug Innovation in Switzerland?
• Stefan Kohler (PhD), Attorney-at-law, Head of Life Sciences Group, Vischer Ltd, Basel/Zurich

Personalised Medicine and Impact of New Technologies

Monday, September 10

The Road to Personalised Precision Health Care
• Ernst Hafen (PhD), Professor, former President of The Federal Institute of Technology Zurich, Head Institute of Molecular Systems Biology, Federal Institute of Technology Zurich, Zurich

Personalized Medicine and the Personal Drug Response Profile
• Urs A. Meyer (MD), Professor of Pharmacology, Biozentrum, University of Basel, Basel
2 Healthcare: Medicine and Research/Innovative Treatments

Haematology/Oncology  
Tuesday, September 11

Chairs:  
• Christoph Renner (MD), Professor, Head Department of Internal Medicine Oncology, University Hospital Zurich, Zurich
• Jakob Passweg (MD), Professor, Head Department of Hematology University Hospital Basel, President Swiss Cancer League, Basel

Cell Based and Gene Therapies  
Tuesday, September 11

- Autologous Stemcell Programme
  - Christoph Renner (MD), Professor, Head Department of Internal Medicine-Oncology, University Hospital Zurich

- Platelet-rich Plasma and Collagen Preparation in Treating Patients with Nonhealing Chronic Wounds
  - Vladimir N. Obolensky (MD), City Clinical Hospital N*13, Russian National Research Medical University, Moscow

- Regenerative Medicine and Biotechnology
  - Vitaly Morozov (MD), Professor, Advanced Medical Technologies Centre (ICBFM), Novosibirsk

- The Future of Stem Cell Transplantation
  - Jakob Passweg (MD), Professor, Head Department of Hematology University Hospital Basel, President Swiss Cancer League, Basel

- Gene Therapy with Adoptive T-Cell Transfer
  - Ulf Petrausch, (MD), Professor, Senior Physician, Division of Immunology, University Hospital Zurich, Zurich

- Optimised gene constructs for expression of therapeutic genes in liver cells
  - Chavdar Pavlov, (MD), Professor and Deputy Director of the Clinic of Internal Diseases Propaedeutics, Gastroenterology and Hepatology, „Sechenov“ First Moscow Medical State University, Moscow
DAY 2

2 Healthcare: Medicine and Research/Innovative Treatments

Oncology – Translational Research

Tuesday, September 11

Chairs:
• David Zaridze (MD, DSc), Deputy Director, Russian N. N. Blokhin Cancer Research Centre, RAMS, Invited Professor of Epidemiology, Oxford University, Senior Scientist, International Prevention Research Institute, Lyon
• Christoph Rochlitz (MD), Professor, Head Oncology, University Hospital Basel, Basel

Molecular Epidemiology of cancer: prospects for translation
• David Zaridze (MD), Professor, Deputy Director, Russian N. N. Blokhin Cancer Research Centre, Head of Department of Epidemiology and Prevention, Moscow

Here we need talks on breast, colon, lung cancer etc.
• Christoph Rochlitz (MD), Professor, Head Oncology, University Hospital Basel, Basel

Evolving therapeutic concepts in renal cell carcinoma
• Frank Stenner (MD), Senior Physician of Oncology Department, University Hospital Basel, Basel

Stereotactic radiotherapy and radiosurgery: Facts and visions
• Daniel Aebersold (MD), Professor, Director and Chairman, Department of Radiation Oncology, University of Bern, Inselspital, Bern

Molecular analyses of sensitivity to target therapy in patients with lung, colorectal cancer and GISTs
• Natalia Mazurenko (MD), Professor, Head of the Department of Oncogenomics, Russian N. N. Blokhin Cancer Research Centre, Moscow

Predictive biomarkers and targeted therapy in advanced non-small cell lung cancer
• Sacha Rothschild (MD), Senior Physician of Oncology Department, University Hospital Basel, Basel

Gynaecologic cancer – a brief update and new treatment options
• Marcus Vetter (MD), Professor, Chairman, Centre for Gynecological Oncology, University Hospital Zurich, Zurich

From Systems Biology to Personalised Medicine: How to identify “actionable” drug targets and translate them into personalised treatments in clinic?
• Tatjana Nikoljskaya (MD), Head of Laboratory for Translational Research & Personalised Medicine, Department of Molecular Biology and Physics at MIPT, Dolgoprudnyj, Moscow Region

Tissue-specific transcription factor HNF4a: from experimental tool to prognostic marker
• Natalia Lazarevich (MD), Institute of Carcinogenesis, Russian N. N. Blokhin Cancer Research Centre, Moscow

Vascularisation of the surface covering epithelium in cancer patients: a new insight into a possible mechanism of cancer pathogenesis
• Apollon Karseladze (MD), Head Department of Pathology, Russian N. N. Blokhin Cancer Research Centre, Moscow

Understanding and treating triple negative breast cancer
• Mona Frolova (MD), Scientific Fellow, Department of Clinical Pharmacology, Russian N. N. Blokhin Cancer Research Centre, Moscow

Chemotherapy for pure prognosis non-seminoma germ-cell tumours
• Michail Fedyanin (MD), Scientific fellow, Department of Clinical Pharmacology, Russian N. N. Blokhin Cancer Research Centre, Moscow

Disruption of stable cell-cell adhesion and acquisition of a motile phenotype in neo-plastically transformed epithelial cells: the role of the actin cytoskeleton and E-cadherin-based adherens junctions
• Natalia Glushankova (MD), Leading Scientific Fellow, Laboratory of Mechanisms of Carcinogenesis, Carcinogenesis Institute of Carcinogenesis, Russian N. N. Blokhin Cancer Research Centre, Moscow

CARDIOVASCULAR

Tuesday, September 11

Chairs:
• Thierry Carrel (MD), Professor, Chairman, Centre for Cardiac Surgery of the Universities Berne and Basel, Berne
• Sergei L. Dzemeshkevich (MD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

Sudden cardiac death/resuscitation and sudden death prevention among sportsmen and general population
• Lars Engelberger (MD), Professor, Clinic for Cardiovascular Surgery, University Hospital Berne, Berne

Heart Transplantation: State of the Art in Russia
• Eugene Katz (MD), Specialist in Cardiology, University Hospital Lausanne, Lausanne

Heart Transplantation: State of the Art in Russia
• Martyn Szynar (MD), Professor, University Hospital Berne, Berne

1. Heart Failure: Symmetric Volume Reduction of the Left Atrium for Patients with Cardiomyopathy
• Sergei L. Dzemeshkevich (MD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

1. Heart Failure: Symmetric Volume Reduction of the Left Atrium for Patients with Cardiomyopathy
• Sergei L. Dzemeshkevich (MD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

1. Heart Failure: Symmetric Volume Reduction of the Left Atrium for Patients with Cardiomyopathy
• Sergei L. Dzemeshkevich (MD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

1. Heart Failure: Symmetric Volume Reduction of the Left Atrium for Patients with Cardiomyopathy
• Sergei L. Dzemeshkevich (MD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

LVAD: Bridge and Destination Options
• Apollon Karseladze (MD), Professor, Head Department of Pathology, Russian N. N. Blokhin Cancer Research Centre, Moscow

2. EVAR: Type B Dissection: pro’s and con’s
• Sergei A. Abubov (MD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

3. The Older Patient with Valve Disease: Surgical and Interventional Techniques
• Martin Czerny (MD), Professor, University Hospital Berne, Berne

1. Heart Failure: Symmetric Volume Reduction of the Left Atrium for Patients with Cardiomyopathy
• Sergei L. Dzemeshkevich (MD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

4. Genetics and the cardiovascular system – Cardiological Masks of Inherited Neuromuscular Disorders
• Nina V. Zaklyazminskaya (MD, PhD), Head of Medical Genetics Laboratory, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

The Role of the Genetician in Aortic Diseases
• Andrey Shevela (PhD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

Current Trends in Pftology
• Gabor Matyas (MD), Professor, Centre for Cardiovascular Genetic and Gene Diagnostics, Schlieren

1. Heart Failure: Symmetric Volume Reduction of the Left Atrium for Patients with Cardiomyopathy
• Sergei L. Dzemeshkevich (MD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

2. EVAR: Type B Dissection: pro’s and con’s
• Sergei A. Abubov (MD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

3. The Older Patient with Valve Disease: Surgical and Interventional Techniques
• Thomas F. Luescher (MD), Professor, Chairman of Cardiology and Cardiovascular Physiology, University Hospital Zurich, Zurich

4. Genetics and the cardiovascular system – Cardiological Masks of Inherited Neuromuscular Disorders
• Friedrich Eckstein (MD), Professor, Clinic for Cardiac Surgery, University Hospital Basel, Basel

The Role of the Genetician in Aortic Diseases
• Andrey Shevela (PhD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

Current Trends in Pftology
• Gabor Matyas (MD), Professor, Centre for Cardiovascular Genetic and Gene Diagnostics, Schlieren

The Role of the Genetician in Aortic Diseases
• Andrey Shevela (PhD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

Current Trends in Pftology
• Gabor Matyas (MD), Professor, Centre for Cardiovascular Genetic and Gene Diagnostics, Schlieren

The Role of the Genetician in Aortic Diseases
• Andrey Shevela (PhD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

Current Trends in Pftology
• Gabor Matyas (MD), Professor, Centre for Cardiovascular Genetic and Gene Diagnostics, Schlieren

The Role of the Genetician in Aortic Diseases
• Andrey Shevela (PhD), Professor, Petrovsky Russian Research Centre of Surgery, RAMS, Moscow

Current Trends in Pftology
• Gabor Matyas (MD), Professor, Centre for Cardiovascular Genetic and Gene Diagnostics, Schlieren
2 Healthcare: Medicine and Research/Innovative Treatments

**Reproductive Endocrinology**

**Chair:** Bruno Imthurn (MD), Professor, Head Division, Reproductive Endocrinology, University Hospital Zurich, Zurich

- Legal and Regulatory Framework for Reproductive Medicine in Russia & Switzerland – Differences and Similarities
- Bruno Imthurn (MD), Professor, Head Division Reproductive Endocrinology, University Hospital Zurich, Zurich

- Experiences and Results of the Swiss IVF-Registry
- Christian M. H. R. De Geyter (MD), Professor, University Hospital Basel, President Swiss IVF Registry “FIVNAT-CH”, Basel

**Ophthalmology**

**Chairs:** Bernhard Henrich (MD), Department of Ophthalmology, University of Basel, Basel

- Atomic Force Microscopy: New insights into the material properties of the internal limiting membrane
- Bernhard Henrich (MD), Department of Ophthalmology, University of Basel, Basel

- Current Approaches to the Diagnosis and Treatment of the Major Reasons of Blindness: Glaucoma, Cataract, A(MD)/DME
- (Speaker by Novartis)

- High-frequency electric welding of biological tissues in vitreoretinal surgery
- Nikolai Umanets, (MD), Head of Group on Development of New Technologies in Vitreoretinal Surgery, Odessa

- The comparative evaluation of retina functions in the patients with open and closed eye globe traumas
- Maria Chekalova M.V., Moscow Helmholtz Research Institute of Eye Diseases, Moscow

3 Healthcare: New Technologies/Research Programmes & Foresight

**Advanced Laboratory Techniques in Blood Studies/Trends in Nanotechnology**

**Chairs:**
- Dmitri Kuznetsov (MD), Professor, N.I. Russian National Research Medical University, Moscow
- Nicolas Vuilleumier (MD, PhD), Head Clinical Chemistry and Toxicology at the Medical Laboratories, University Hospital Geneva
- Joerg Huwyler (PhD), Professor, Head of the Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel

- Industrial Technologies & Experimental Nanobiotechnologies in Blood Studies
- Vladimir P. Chekhonin (MD), Professor, Chairman Nanobiotechnology, N. I. Pirogov National Research Medical University, Moscow

- Radiospectroscopic Studies of Blood Plasma Proteins and Cells: Free Radical and Antioxidant Aspects
- Anatoly N. Osipov (MD), Professor, Head of Department Medical Biophysics, N. I. Pirogov Russian National Research Medical University, Moscow

- Luminiscent Assays in Blood Tests: Probes and Kinetic Measurements
- Yuri A. Vladimirov (MD), Professor, Head of Department Biophysics, Faculty of Fundamental Medicine, M. V. Lomonosov Moscow State University, Moscow

- Anti-apoapolipoprotein A-1 IgG as an emergent prognostic marker of cardiovascular risk: a translational approach
- Nicolas Vuilleumier (MD, PhD), Head Clinical Chemistry and Toxicology at the Medical Laboratories, University Hospital Geneva

- Molecular Aberrations in Histiocytic Disorders
- Alexey A. Maschan (MD), Professor, Deputy Director, Russian Federal Research Centre for Pediatric Haematology, Oncology & Immunology, Moscow

- Combi-drug formulations for phenotyping cocktails
- Maxim Puchkov (PhD), Division of Pharmaceutical Technology, University of Basel

- Nanocarriers: Are they really promising in Pharmacology?
- Dmitry A. Kuznetsov (MD), Professor, N.I. Pirogov Russian National Research Medical University, Moscow

- Anatoly L. Buchachenko, Professor, RAS Institute for Chemical Physics, Moscow

- Nanopharmaceuticals: Trends in Marketing and Medicinal Research
- Vladimir P. Chekhonin (MD), Professor, Head of Medical Nanobiotechnology, N. I. Pirogov Russian National Research Medical University, Moscow

- Nanotech approaches – Hemopoetic Progenitor and Neuronal Stem Cells in Cancer Therapy
- Vladimir P. Chekhonin (MD), Professor, N. I. Pirogov Russian National Research Medical University, Moscow
DAY 2

3 Healthcare: New Technologies/Research Programmes & Foresight

Technical Advances over the next Decade

Moderation: • Ernst Hafen (PhD), Professor, former President of The Federal Institute of Technology Zurich, Head Institute of Molecular Systems Biology, Federal Institute of Technology Zurich, Zurich

Roundtable: Advances in Health Care will not only grow out of the existing medical system but come from neighbouring fields such as Mobile Computing, Computer Science, Robotics, Social Media and Ethics.

DAY 2

5 Industry, Investors and Inventors

From Research to Products

Russian Federation:
• Impact of the huge domestic market on innovation and the Swiss/Russian healthcare industry
• The Russian role in the international healthcare market with a focus on...
• Technology Development: Aseptic Isolators in the Healthcare Industry

Switzerland:
• Highly specialized industry delivering high quality products in a small home market with high pressure for internationalisation and export. (Technology driven Innovation)
• The Swiss role in the international healthcare market

New laser microscope for biomedical live cell research and drug discovery
• Pavel A. Osipov, General Director Laboratory AMFORA, Moscow

GMP and Safety Compliant Production of Sterile, Sterile Toxic or Toxic Pharmaceutical Products in Hospitals and the Industry
• Paul Ruffieux (MD), Vice President SKAN AG, Allschwil

Integration of Various Medical Information Systems
• Matthias Stromberger, Strategy Management and Owner of Dorner Health IT Solutions

Closing Plenary

Results

• Results with short presentations
• Further procedure 2012/2013 and next steps
• Invitation 2013
We are grateful to our Sponsors

- Gazprombank  
  General Sponsor

- Merck, Merck Serono division of Merck KGaA
- Novartis  
  Strategic Sponsors

- Basel University Hospital
- Basel University
- Ferring  
  Sponsor

- Medtech Switzerland
- Swiss International Air Lines
- Vischer Ltd.  
  Co-Sponsors

- Medvestnik
- Nasha Gazeta.ch
- Russian Union of Innovation and Technology Centres
- Zelenograd Centre of Innovation and Technology  
  Media-Sponsors